The Journal of Heart and Lung Transplantation
Volume 25, Issue 5 , Pages 518-522 , May 2006

Early Renal Benefit of Rapamycin Combined With Reduced Calcineurin Inhibitor Dose in Pediatric Heart Transplantation Patients

  • Ian C. Balfour, MD

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Saint Louis University Health Sciences Center, St. Louis, Missouri, USA
    • Corresponding Author InformationReprint requests: Ian C. Balfour, MD, Cardinal Glennon Children’s Hospital, 1465 South Grand Boulevard, St. Louis, MO 63104. Telephone: 314-577-5633. Fax: 314-268-4035
    • ,
  • Sopheak W. Srun, MPH

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Saint Louis University Health Sciences Center, St. Louis, Missouri, USA
    • ,
  • Ellen G. Wood, MD

      Affiliations

    • Division of Nephrology, Department of Pediatrics, Saint Louis University Health Sciences Center St. Louis, Missouri, USA
    • ,
  • Craig W. Belsha, MD

      Affiliations

    • Division of Nephrology, Department of Pediatrics, Saint Louis University Health Sciences Center St. Louis, Missouri, USA
    • ,
  • Donna L. Marshall, RN

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Saint Louis University Health Sciences Center, St. Louis, Missouri, USA
    • ,
  • Barbara R. Ferdman, MD

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Washington University Medical Center, St. Louis, Missouri

Received 17 May 2005 ,Revised 23 September 2005 ,Accepted 16 January 2006.

References 

  1. Halloran PF , Miller LW . In vivo immunosuppressive mechanisms . J Heart Lung Transplant . 1996;15:959–971
  2. Pietra BA , Boucek MM . Immunosuppression for pediatric cardiac transplantation in the modern era . Prog Pediatr Cardiol . 2000;11:115–129
  3. Davies D , Bittmann I , Pardo J . Histopathology of calcineurin inhibitor-induced nephrotoxicity . Transplantation . 2000;69(12 Suppl):SS11
  4. Goldstein DJ , Zuech N , Sehgal V , et al.   Cyclosporine-associated end stage nephropathy after cardiac transplantation (incidence and prognosis) . Transplantation . 1997;63:664–668
  5. Sindhi R . Sirolimus in pediatric transplant recipients . Transplant Proc . 2003;35(Suppl 3A):113S–114S
  6. Sindhi R , Webber S , Venkataramanan R , et al.   Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus . Transplantation . 2001;72:851–855
  7. MacDonald AS . Management strategies for nephrotoxicity . Transplantation . 2000;69:5531–5536
  8. Schwartz GJ , Haycock GB , Edelmann CM , Spitzer A . A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine . Pediatrics . 1976;58:259–263
  9. Sehgal SN . Rapamune (mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression) . Clin Biochem . 1998;31:335–339
  10. Groetzner J , Meiser B , Landwehr P , et al.   Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac transplant recipients with chronic renal failure . Transplantation . 2004;77:568–573
  11. Trosch F , Rothenburger M , Schneider M , Welp H , Etz C , Wilhelm M . First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation . Thorac Cardiovasc Surg . 2004;52:163–168
  12. Snell GI , Levvey BJ , Chin W , et al.   Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal failure . J Heart Lung Transplant . 2002;21:510–546
  13. Lobach NE , Pollock-Barziv SM , West LJ , Dipchand AI . Sirolimus immunosuppression in pediatric heart transplant recipients (a single center experience) . J Heart Lung Transplant . 2005;24:184–189
  14. Mancini D , Pinney S , Burkhoff D , et al.   Use of rapamycin slows progression of cardiac transplantation vasculopathy . Circulation . 2003;108:48–53
  15. Murgia MG , Jordan S , Kahan BD . The side effect profile of sirolimus (a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients) . Kidney Int . 1996;49:209–216
  16. McOmber D , Ibrahim J , Lublin DM , et al.   Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation. Treatment with plasmapheresis and OKT3 . J Heart Lung Transplant . 2004;23:552–557
  17. Webber SA , Naftel DC , Parker J , et al.   Late rejection episodes more than 1 year after pediatric heart transplantation (Risk factors and outcomes) . J Heart Lung Transplant . 2003;22:869–875

PII: S1053-2498(06)00079-9

doi: 10.1016/j.healun.2006.01.004

The Journal of Heart and Lung Transplantation
Volume 25, Issue 5 , Pages 518-522 , May 2006

Article Tools

* Image Usage & Resolution